Innovative Medicine — Research and development expense
Business Segments · Research and development expenseJohnson & Johnson Innovative Medicine — Research and development expense increased by 2.6% to $2.94B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 30.1%, from $4.21B to $2.94B. Over 2 years (FY 2022 to FY 2024), Innovative Medicine — Research and development expense shows an upward trend with a 7.8% CAGR.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityStable
First reportedQ1 2022
Last reportedQ3 2025
How to read this metric
Higher investment is generally positive for long-term growth, provided it leads to successful pipeline progression.
Detailed definition
Tracks the investment in scientific research, clinical trials, and product development within the Innovative Medicine se...
Peer comparison
Standard 'R&D Expense' reported by pharmaceutical companies for their drug development segments.
Metric ID:
jnj_segment_innovative_medicine_research_and_development_expenseHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.91B | $2.91B | $2.91B | $2.91B | $2.99B | $2.99B | $2.99B | $2.99B | $2.90B | $2.72B | $4.21B | $3.70B | $2.55B | $2.87B | $2.94B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +2.8% | +0.0% | +0.0% | +0.0% | -3.2% | -6.0% | +54.8% | -12.2% | -31.1% | +12.6% | +2.6% |
| YoY Change | — | — | — | — | +2.8% | +2.8% | +2.8% | +2.8% | -3.2% | -9.0% | +40.9% | +23.6% | -12.0% | +5.4% | -30.1% |
Range$2.55B – $4.21B
CAGR+0.3%
Avg YoY Growth+2.4%
Median YoY Growth+2.8%
Current Streak2 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — research and development expense?
- Johnson & Johnson (JNJ) reported innovative medicine — research and development expense of $2.94B in Q3 2025.
- How has Johnson & Johnson's innovative medicine — research and development expense changed year-over-year?
- Johnson & Johnson's innovative medicine — research and development expense decreased by 30.1% year-over-year, from $4.21B to $2.94B.
- What is the long-term trend for Johnson & Johnson's innovative medicine — research and development expense?
- Over 2 years (2022 to 2024), Johnson & Johnson's innovative medicine — research and development expense has grown at a 7.8% compound annual growth rate (CAGR), from $11.64B to $13.53B.
- What does innovative medicine — research and development expense mean?
- The amount spent on research and development for new medicines within the segment.